Intra-cellular Therapies Inc.

Advice for CEOs and CFOs as they navigate the year ahead

Public Markets Preview: Will political uncertainty resolve in biotech’s favor or lead to economically damaging policy?

Gainers, decliners among companies presenting at this week’s J.P. Morgan Healthcare Conference

The buzz of Asia innovation and upbeat hopes for deals outshadow concerns over IPOs, FDA and more. Fewer people, better meetings

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

BioCentury’s Deals Report surveys deals by GSK, Idrx, Lilly, Scorpion, Lantheus, Telix, Gilead, Leo, CBC Group and more

Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years

J&J’s nearly $15B neuro buy kicks off biotech meeting. Plus: Washington insights and 2024’s key FDA approvals

Plus: Sarena becomes COO of 89bio

Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura